Active substance
Cyproterone
- SFDA 2
- Health Canada 4
- NHS prices 2
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ANDROCUR 50MG TAB | 50 mg | Tablet · Oral use | 20 Blister | SAR 63.55 | NCE · Prescription | BAYER PHARMA AG | Invalid · Not Marketed |
| ANDROCUR 50MG TAB. | 50 mg | Tablet · Oral use | 20 Bottle | SAR 94.00 | NCE · Prescription | BAYER SANTE FAMILIALE | Withdrawn by MAH · Not Marketed |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ANDROCUR | 00704431 | 50 MG | TABLET · ORAL | AMDIPHARM LIMITED |
| CYPROTERONE | 02245898 | 50 MG | TABLET · ORAL | AA PHARMA INC |
| MED-CYPROTERONE | 02390760 | 50 MG | TABLET · ORAL | GENERIC MEDICAL PARTNERS INC |
| RIVA-CYPROTERONE | 02395797 | 50 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Cyproterone 100mg tablets | £132.57 | 84 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cyproterone 50mg tablets | £98.75 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- MHRA 29 Jun 2020 Cyproterone acetate: new advice to minimise risk of meningioma
Risk of meningioma with cyproterone acetate increases with increasing cumulative dose. Use of cyproterone is contraindicated in patients with previous or current meningioma (for all indications) and should only be considered for control of libido in severe hypersexuality or paraphilias in adult men when other interventions are inappropriate.
Combinations containing Cyproterone
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.